| [1] Higuchi K, Phan A, Ajani J A.Gastric cancer:advances in adjuvant and adjunct therapy[J].Curr Treat Options Oncol,2003,4(5):413-419.[2] 秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652.[3] 曹妮达,赵爱光,朱莹杰,等.进展期胃癌化疗疗效的中国文献分析[J].世界华人消化杂志,2008,16(4):436-442.[4] Therasse P, Arbuck S G, Eisenhauer E A, et al. New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States.National Cancer Institute of Canada[J].J Natl Cancer Inst,2000,92(3):205-216.[5] Wagner A D,Grothe W,Haerting J, et al.Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data[J].J Clin Oncol,2006,24(18):2903-2909.[6] 曹锋,王亚军,李菲.胃癌辅助放化疗研究进展[J].现代肿瘤医学,2010,18(1):202-204.[7] 郭锰; 进展期胃癌术后腹腔化疗的临床疗效分析[J].中华肿瘤防治杂志,2011,18(5):374-376.[8] 甄四虎, 侯会池,王少文,等.腹腔镜辅助下进展期胃癌根治术56例分析[J]. 解放军医药杂志,2012,24(3):32-34.[9] 张国伟,宋丽杰.进展期胃癌化疗现状与进展[J]. 临床药物治疗杂志,2009,7(5):14-18.[10] Koizumi W, Kurihara M, Nakano S, et al. Phase Ⅱ study of S-1,a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group[J]. Oncology, 2000,58(3): 191-197.[11] Tanaka F, Fukuse T, Wada H, et al.The History,Mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents[J].Curr Pham Biotechnol,2000,1(2):137-164.[12] Terashima M, Fujiwara H, Takagane A, et al. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer[J].Gastric Cancer,2003,6 suppl 1:71-81.[13] Yoshisue K, Hironaga K, Yamaguchi S, et al.Reduction of 5-fluorouracil (5-Fu) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase(TS) in GI tissue by repeated simultaneous administration of potassium oxonate (OXO) in rat[J]. Cancer Chemother Pharmacol,2000,46(1):51-56.[14] 林万隆,陈强.奥沙利铂的药理作用及临床应用[J].中国肿瘤临床, 2000,27(11):872-874.[15] 林俊,朱俊,黄世明.奥沙利铂联合ELF方案治疗晚期胃癌的临床观察[J].中华肿瘤防治杂志,2011,18(2):140-141.[16] Koizumi W, Narahara H, Hara T, et al.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial):a phase Ⅲ trial[J].Lancet Oncol,2008,9(3):215-221.[17] Zaniboni A, Meriggi F. The emerging role of oxaliplatin in the treatment of gastric cancer[J].J Chemother,2005,17(6):656-662. |
